Corticosteroids for COVID-19: worth it or not?
Fariya AkterYusha ArafMohammad Jakir HosenPublished in: Molecular biology reports (2021)
Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in patients causing significant morbidity and mortality. To diminish systemic hyper inflammation, a few physicians and researchers have utilized corticosteroids. Corticosteroid implementation has increased after the publication of interim guidelines regarding corticosteroid use in COVID-19 patients by WHO, despite the remaining controversies regarding long-term side effects and disease progression capability of corticosteroids. In different studies, the implementation of corticosteroids on COVID-19 patients revealed controversial results, which require further intensive research. This review will present the current outcomes and possibilities of using corticosteroids to treat COVID-19 patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- primary care
- end stage renal disease
- coronavirus disease
- healthcare
- ejection fraction
- newly diagnosed
- oxidative stress
- chronic kidney disease
- type diabetes
- adipose tissue
- diabetic rats
- patient reported outcomes
- clinical practice
- peritoneal dialysis
- body mass index
- metabolic syndrome
- physical activity
- weight gain
- insulin resistance
- case control